Rain Therapeutics (RAIN)

Rain Therapeutics Stock Analysis & Ratings

RAIN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.22 - $22.22
Previous Close$2.83
Average Volume (3M)72.73K
Market Cap$75.08M
P/E Ratio-1.2
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)-2.34



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Rain Therapeutics’s price range in the past 12 months?
Rain Therapeutics lowest stock price was $2.22 and its highest was $22.22 in the past 12 months.
    What is Rain Therapeutics’s market cap?
    Rain Therapeutics’s market cap is $75.08M.
      What is Rain Therapeutics’s price target?
      The average price target for Rain Therapeutics is $16.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $16.00 ,the lowest forecast is $16.00. The average price target represents 465.37% Increase from the current price of $2.83.
        What do analysts say about Rain Therapeutics?
        Rain Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Rain Therapeutics’s upcoming earnings report date?
          Rain Therapeutics’s upcoming earnings report date is Aug 09, 2022 which is in 83 days.
            How were Rain Therapeutics’s earnings last quarter?
            Rain Therapeutics released its earnings results on May 04, 2022. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.698 by $0.038.
              Is Rain Therapeutics overvalued?
              According to Wall Street analysts Rain Therapeutics’s price is currently Undervalued.
                Does Rain Therapeutics pay dividends?
                Rain Therapeutics does not currently pay dividends.
                What is Rain Therapeutics’s EPS estimate?
                Rain Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Rain Therapeutics have?
                Rain Therapeutics has 26,530,000 shares outstanding.
                  What happened to Rain Therapeutics’s price movement after its last earnings report?
                  Rain Therapeutics reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.698. Following the earnings report the stock price went down -16.279%.
                    Which hedge fund is a major shareholder of Rain Therapeutics?
                    Among the largest hedge funds holding Rain Therapeutics’s share is Perceptive Advisors LLC. It holds Rain Therapeutics’s shares valued at 13M.


                      Rain Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(465.37% Upside)
                      Moderate Buy
                      The Rain Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Rain Therapeutics

                      Rain Therapeutics Inc is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which they are able to genetically select patients they believe will most likely benefit. Its lead product candidate, RAIN-32 is a small molecule, oral inhibitor of mouse double minute 2, which is oncogenic in numerous cancers.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis